Eli Lilly (LLY) shares climbed higher Thursday after the pharmaceutical giant released new data on its weight loss drug Mounjaro, which helps people with type 2 diabetes tackle obesity.
A large trial showed that patients lost, on average, up to 16% of their body weight using Tirzepatide.
The popularity of drugs like Novo Nordisk's (NVO) Ozempic and Wegovy have surged in the last two years, according to Goldman Sachs.
It's clear there's a growing market for weight loss drugs.
Key Video Highlights:
0:00:12 - Huge market for weight loss drugs
0:00:58 - The path for FDA approval
